Mangoceuticals (MGRX) versus The Competition Financial Analysis
by Kim Johansen · The Markets DailyMangoceuticals (NASDAQ:MGRX – Get Free Report) is one of 18 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its peers? We will compare Mangoceuticals to similar businesses based on the strength of its institutional ownership, risk, profitability, earnings, valuation, dividends and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Mangoceuticals and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
| Mangoceuticals Competitors | 36 | 288 | 416 | 147 | 2.76 |
As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 14.80%. Given Mangoceuticals’ peers higher possible upside, analysts clearly believe Mangoceuticals has less favorable growth aspects than its peers.
Risk and Volatility
Mangoceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ peers have a beta of 4.14, indicating that their average stock price is 314% more volatile than the S&P 500.
Earnings & Valuation
This table compares Mangoceuticals and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Mangoceuticals | $866,792.00 | -$9.21 million | -5.84 |
| Mangoceuticals Competitors | $2.39 billion | $82.32 million | 13.32 |
Mangoceuticals’ peers have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Mangoceuticals and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
| Mangoceuticals Competitors | -816.62% | -48.14% | -36.60% |
Institutional & Insider Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by company insiders. Comparatively, 27.3% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Mangoceuticals peers beat Mangoceuticals on 9 of the 10 factors compared.
Mangoceuticals Company Profile
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.